Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis

Matthew P. Cheng; José L. Orejas; Esther Arbona-Haddad; Tyler D. Bold; Isaac H. Solomon; Kaiwen Chen; Alisha Pandit; Amanda E. Kusztos; Kaelyn C. Cummins; Alexis Liakos; Francisco M. Marty; Sophia Koo; Sarah P. Hammond

doi:10.1111/myc.13013

Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis

Matthew P. Cheng, José L. Orejas, Esther Arbona-Haddad, Tyler D. Bold, Isaac H. Solomon, Kaiwen Chen, Alisha Pandit, Amanda E. Kusztos, Kaelyn C. Cummins, Alexis Liakos, Francisco M. Marty, Sophia Koo, Sarah P. Hammond

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.

Original language	English (US)
Pages (from-to)	58-64
Number of pages	7
Journal	Mycoses
Volume	63
Issue number	1
DOIs	https://doi.org/10.1111/myc.13013
State	Published - Jan 1 2020
Externally published	Yes

Bibliographical note

Funding Information:
MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Santé Québec.

Funding Information:
MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Sant? Qu?bec.

Publisher Copyright:
© 2019 Blackwell Verlag GmbH

Keywords

Aspergillus
invasive aspergillosis
isavuconazole
posaconazole
voriconazole

Access

10.1111/myc.13013

OpenUrl availability

Full text

Cite this

@article{82fdac40ca744041baec1775b63adb20,

title = "Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis",

abstract = "In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.",

keywords = "Aspergillus, invasive aspergillosis, isavuconazole, posaconazole, voriconazole",

author = "Cheng, {Matthew P.} and Orejas, {Jos{\'e} L.} and Esther Arbona-Haddad and Bold, {Tyler D.} and Solomon, {Isaac H.} and Kaiwen Chen and Alisha Pandit and Kusztos, {Amanda E.} and Cummins, {Kaelyn C.} and Alexis Liakos and Marty, {Francisco M.} and Sophia Koo and Hammond, {Sarah P.}",

note = "Funding Information: MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Sant{\'e} Qu{\'e}bec. Funding Information: MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Sant? Qu?bec. Publisher Copyright: {\textcopyright} 2019 Blackwell Verlag GmbH",

year = "2020",

month = jan,

day = "1",

doi = "10.1111/myc.13013",

language = "English (US)",

volume = "63",

pages = "58--64",

journal = "Mycoses",

issn = "0933-7407",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Use of triazoles for the treatment of invasive aspergillosis

T2 - A three-year cohort analysis

AU - Cheng, Matthew P.

AU - Orejas, José L.

AU - Arbona-Haddad, Esther

AU - Bold, Tyler D.

AU - Solomon, Isaac H.

AU - Chen, Kaiwen

AU - Pandit, Alisha

AU - Kusztos, Amanda E.

AU - Cummins, Kaelyn C.

AU - Liakos, Alexis

AU - Marty, Francisco M.

AU - Koo, Sophia

AU - Hammond, Sarah P.

N1 - Funding Information: MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Santé Québec. Funding Information: MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Sant? Qu?bec. Publisher Copyright: © 2019 Blackwell Verlag GmbH

PY - 2020/1/1

Y1 - 2020/1/1

N2 - In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.

AB - In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.

KW - Aspergillus

KW - invasive aspergillosis

KW - isavuconazole

KW - posaconazole

KW - voriconazole

UR - http://www.scopus.com/inward/record.url?scp=85074848693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074848693&partnerID=8YFLogxK

U2 - 10.1111/myc.13013

DO - 10.1111/myc.13013

M3 - Article

C2 - 31587405

AN - SCOPUS:85074848693

SN - 0933-7407

VL - 63

SP - 58

EP - 64

JO - Mycoses

JF - Mycoses

IS - 1

ER -

Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this